Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02793700
Other study ID # 1604640151
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2016
Est. completion date March 2022

Study information

Verified date March 2022
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Respiratory distress syndrome (RDS) is a life-threatening condition for premature neonates. Antenatal glucocorticoids have been used clinically in women with threatened preterm birth to accelerate lung maturation for more than 40 years. The current treatment strategy for women with threatened preterm delivery is for a standard, "one size fits all" dosing with either betamethasone (BMZ) or dexamethasone. It is well known that pregnancy introduces additional variability in response to medication therapy with different physiological changes and alterations in the activity of drug metabolizing enzymes. The objective of this project is to evaluate the pharmacokinetic (PK), pharmacodynamic, and pharmacogenetic parameters of betamethasone (BMZ) and determine the differences in response and benefit in pregnancy. An individualized dosing approach to medications in pregnancy, such as BMZ, is crucial to optimize efficacy of this important medication.


Description:

After consent, a maternal sample of whole blood will be obtained for DNA isolation. Investigators will collect plasma samples at 4 time points on all participants. These will be done at baseline (pre-dose), and 0.5-2 hours, 4-6 hours, and 22-24 hours after the first dose of BMZ is administered. Investigators will obtain serum for estriol measurement on all participants before or within 2 hours of antenatal corticosteroid administration and about 24 hours after each dose is given (betamethasone is administered as 2 doses 24 hours apart). Investigators will obtain a saliva sample for measurement of estriol at the same times. Participants will be offered optional participation in a more detailed PK portion of the study. Participants who consent to this part of the study will have additional plasma samples obtained at a schedule of sampling of approximately 10-15 hours after the first dose and then 6-8 hours, 24, and 48 hours after the 2nd dose. One sample will be collected at each of these times. At the time of delivery, umbilical cord blood will be collected before being discarded for DNA, serum and plasma. Four placenta sections will be collected. A maternal blood sample will also be obtained for serum and plasma. If the investigators are unable to obtain umbilical cord blood, a buccal swab will be collected from the baby for DNA extraction. A chart review will be done on the infant within 30 days of birth to review and record neonatal outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date March 2022
Est. primary completion date March 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Gestational age between 23-34 weeks with a diagnosis of threatened preterm labor or preterm premature rupture of membranes, or other diagnosis with a high likelihood of preterm delivery where the provider is recommending administering antenatal corticosteroids - Singleton gestation - Live fetus at the time of enrollment - Being administered antenatal corticosteroids to enhance lung maturity - Ability to provide written informed consent to participate in the study Exclusion Criteria: - Maternal age <18 years old - Major congenital anomalies - Known severe abruptio placentae at the time of enrollment - Multiple gestations - Hepatic failure (history of hepatic failure, cirrhosis or 2- fold increase in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) - Renal failure (serum creatinine > 2 mg/dl)

Study Design


Locations

Country Name City State
United States Eskenazi Hospital Indianapolis Indiana
United States IUH Methodist Hospital Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnosis of respiratory distress syndrome The diagnosis of RDS made by the neonatologist staff based on clinical criteria up to 30 days of life
See also
  Status Clinical Trial Phase
Completed NCT00457925 - Absorption, Distribution, Metabolism And Excretion Study For GSK221149A Phase 1
Completed NCT05602883 - Music Therapy in the Threat of Premature Birth N/A
Completed NCT02451228 - Indomethacin PK and PD Therapy in Pregnancy
Not yet recruiting NCT00425867 - PAR Family Polymorphisms and Placental Invasion Disorders N/A
Terminated NCT00306462 - Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor N/A
Completed NCT00873314 - Bed Rest for Threatened Preterm Labor. Pilot Study N/A
Withdrawn NCT00120640 - Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate N/A
Completed NCT03223324 - Performance of the Monica Novii Wireless Patch System in Threatened and Actual Pre-Term Labour
Not yet recruiting NCT01022619 - The Association Between High Risk Pregnancy and Sleep-disordered Breathing N/A
Withdrawn NCT02569216 - Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth Phase 1
Recruiting NCT05477381 - Cervical Softening and the Prediction of Preterm Birth
Completed NCT03057275 - Performance of the Monica Novii Wireless Patch System in Pre-term Labor